NOVA™ NGS

https://www.bgi.com/global/molecular-genetics/nova-newborn-screening/nova-newborn-genetic-screening/

Each year, an estimated 7.9 million babies worldwide are born with birth defects, many of which appear healthy at birth and come from families with no history of the disorder. Many affected babies are not identified until the appearance of severe and often irreversible symptoms later in life.

Detecting a disease at an early stage can enable appropriate and timely medical intervention before more serious and sometimes irreversible health issues are caused.

BGI’s NOVA™ Newborn Genetic Screening Test determines a baby’s risk for 87 inherited disorders, as well as providing personalized genetic information on the likely response of 32 pediatric drugs.

SUITABLE FOR:

Parents who want a comprehensive genetic screen for their baby; Parents who would like to learn their baby’s drug-related genetic status; Babies who have missed out on regular screening; Babies from parents with a family history of inherited disorders or from a population identified as at higher risk for genetic disease

TA TIME:
25 working days

SAMPLE:
Saliva, blood spot from heel, cord blood, peripheral blood (children under 5 years)

TECHNOLOGY:
Target region capture, high-throughput sequencing

Why Choose BGI NOVA™ Newborn Genetic Screening?

Fast 15-20 working days to get your genetic report
Accurate-Targeted region capture based NGS with proprietary database
Affordable-Lower price for every family

Note: this test is considered a screening test, not a diagnostic test. Before making any treatment decisions, all patients/guardians should discuss their results with their healthcare provider, who can recommend confirmatory, diagnostic testing where appropriate. This testing service has not been cleared or approved by the US FDA and is not available in the USA.